(Press-News.org) Washington, DC – Researchers at the Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, have found that an arsenic-based agent already FDA-approved for a type of leukemia may be helpful in another hard-to-treat cancer, Ewing's Sarcoma (ES). The research, based on animal studies, also suggests the drug might be beneficial in treating medulloblastoma, a highly malignant pediatric brain cancer.
In the December 22 issue of the Journal of Clinical Investigation, the investigators describe how years of research has uncovered a common pathway in these tumors, known as hedgehog/GLI1. They further detail how they used an existing drug, arsenic trioxide (Trisenox®), to shut down that pathway in mice models of ES and medulloblastoma.
This pathway is also common in other cancers, such as colon, pancreatic, and basal cell skin cancer, among others, says the study's lead investigator, associate professor Aykut Üren, M.D., of Georgetown Lombardi.
"The significance of our finding is that this FDA approved agent can be tested immediately in other cancer types. It is a perfect translational research project," he says. "This laboratory research has immediate clinical implications."
Üren adds that researchers are moving quickly to find an effective inhibitor of the hedgehodg/GL1 pathway because it is so powerful in cancer development. Hedgehog controls cell division in embryonic development, but when it is turned on, and out of control in adult cells, cancer results. Because of that, there are a number of clinical trials underway testing new compounds that inhibit this pathway at the surface membrane of cancer cells, he says.
The compound they tested, however, inhibits the pathway in the nucleus, so it may be effective in cancers that have pathway activation downstream of the membrane molecules, Üren says. "Many of the current clinical trials involve agents that act at the membrane. Ewing sarcoma and colon cancer will not benefit from that approach. Furthermore, medulloblastoma patients treated with hedgehog inhibitors are developing resistance at the membrane level. Therefore, clinical trials can evaluate alternative therapies for patients whose treatment fails with current hedgehog inhibitors," he says.
Arsenic trioxide has been approved for use of acute promyelocyctic leukemia (APL) as a second-line therapy for patients who do not respond to standard therapy.
Arsenic trioxide is generated from processing arsenic compounds, and while a high level of arsenic is known to be carcinogenic, low doses can be therapeutic in selected patients, Üren says. In fact, he says starting in the 17th century, arsenic was the primary therapy for treating leukemia, specifically chronic myelogenous leukemia (CML). He also cites a Dutch population study that concluded low levels of arsenic concentrations in drinking water not only didn't increase cancer incidence in people who drank it, but resulted in a decrease in nonmelanoma skin cancers.
"Like any chemotherapy, high doses of arsenic can be toxic, while lower doses can treat cancer," he says.
In 2009, Üren and his research team, which includes first author Elspeth Beauchamp, Ph.D., showed that the hedgehog/GLI1 pathway is activated in ES. They are now the first to inhibit this pathway by arsenic trioxide in ES, and among the first to show its activity in medulloblastoma.
###
The study was funded by the National Institutes of Health, the Children's Cancer Foundation of Baltimore, and Accelerate Brain Cancer Cure.
The authors report having no personal financial interests related to the study.
About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Lombardi is one of only 40 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Georgetown Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO). In fiscal year 2009-2010, GUMC accounted for 79 percent of Georgetown University's extramural research funding.
END
STANFORD, Calif. — Researchers at the Stanford University School of Medicine have discovered that many cancer cells carry the seeds of their own destruction — a protein on the cell surface that signals circulating immune cells to engulf and digest them. On cancer cells, this "eat me" signal is counteracted by a separate "don't eat me" signal that was described in an earlier study. The two discoveries may lead to better cancer therapies, and also solve a mystery about why a previously reported cancer therapy is not more toxic.
In the study to be published Dec. 22 in Science ...
Sex in mammals is genetically determined. In humans, females have two X chromosomes, while males have one X and one Y chromosome. However, some individuals are born with male genitalia despite having two X chromosomes, a condition known as XX male sex reversal. A team of researchers, led by Paul Thomas, University of Adelaide, Australia, has now determined that overexpression of the Sox3 gene in mice causes frequent XX male sex reversal. The clinical relevance of this was highlighted by the discovery of genomic rearrangements in the regulatory region of the human SOX3 gene ...
The timing of the onset of puberty is linked to levels of nutrition: later onset is associated with malnutrition, while earlier onset is linked to childhood obesity. A team of researchers, led by Carol Elias, at the University of Texas Southwestern Medical Center, Dallas, has now generated data in mice that run counter to current thinking about the molecular pathway by which nutrition status affects the onset of puberty. Further, the team defines a new regulatory pathway for the process, which, if confirmed in humans, could potentially lead to new approaches to treating ...
Arsenic is usually thought of as a poison. Despite this, it has been used in medicine for over 2000 years, and the arsenic compound arsenic trioxide (ATO) is FDA approved for the treatment of acute promyelocytic leukemia. Now, a team of researchers, led by Aykut Üren, at Georgetown University Medical Center, Washington, has generated data using human cancer cell lines that suggest that ATO might also be of benefit to individuals with certain brain tumors or connective tissue tumors.
Certain cancers, in particular brain tumors known as medulloblastomas and connective tissue ...
A multinational research team led by scientists at the National Institutes of Health has found that a genetic variant of a brain receptor molecule may contribute to violently impulsive behavior when people who carry it are under the influence of alcohol. A report of the findings, which include human genetic analyses and gene knockout studies in animals, appears in the Dec. 23 issue of Nature.
"Impulsivity, or action without foresight, is a factor in many pathological behaviors including suicide, aggression, and addiction," explains senior author David Goldman, M.D., ...
CAMBRIDGE, Mass.—Researchers at MIT's Picower Institute for Learning and Memory report for the first time how animals' knowledge obtained through past experiences can subconsciously influence their behavior in new situations.
The work, which sheds light on how our past experiences inform our future choices, will be reported on Dec. 22 in an advance online publication of Nature.
Previous work has shown that when a mouse explores a new space, neurons in its hippocampus, the center of learning and memory, fire sequentially like gunpowder igniting a makeshift fuse. Individual ...
CAMBRIDGE, Mass. (December 22, 2010) – Whitehead Institute researchers have linked hyperactivity in the mechanistic target of rapamycin complex 1 (mTORC1) cellular pathway, to reduced ketone production, which is a well-defined physiological trait of aging in mice.
Their results are reported in the December 23 edition of the journal Nature.
"This is the first paper that genetically shows that the mTORC1 pathway in mammals affects an aging phenotype," says Whitehead Institute Member David Sabatini. "It provides us with a molecular framework to study an aging-related process ...
SANTA CRUZ, CA--A 30,000-year-old finger bone found in a cave in southern Siberia came from a young girl who was neither an early modern human nor a Neanderthal, but belonged to a previously unknown group of human relatives who may have lived throughout much of Asia during the late Pleistocene epoch. Although the fossil evidence consists of just a bone fragment and one tooth, DNA extracted from the bone has yielded a draft genome sequence, enabling scientists to reach some startling conclusions about this extinct branch of the human family tree, called "Denisovans" after ...
EDITOR'S PICK: What sex are you?
Sex in mammals is genetically determined. In humans, females have two X chromosomes, while males have one X and one Y chromosome. However, some individuals are born with male genitalia despite having two X chromosomes, a condition known as XX male sex reversal. A team of researchers, led by Paul Thomas, University of Adelaide, Australia, has now determined that overexpression of the Sox3 gene in mice causes frequent XX male sex reversal. The clinical relevance of this was highlighted by the discovery of genomic rearrangements in the regulatory ...
BOSTON (December 22, 2010) -- Is quality in the eye of the beholder?
Researchers at Harvard Medical School and Massachusetts General Hospital have found wide disparities among four common measures of hospital-wide mortality rates, with competing methods yielding both higher- and lower-than-expected rates for the same Massachusetts hospitals during the same year.
The findings, published Dec. 23 in a special article in the New England Journal of Medicine, stoke a simmering debate over the value of hospital-wide mortality rates as a yardstick for health care quality. ...
